OTHER GROUP COMPANIES
market

Dishman Carbogen Amcis welcomes results of Clinical Research Study in vitamin D deficiency/insufficiency with Covid patient

The study showed that patients receiving the 25-hydroxy metabolite had, in comparison to those receiving a placebo, demonstrably more favourable development of their immunological defence against COVID-19.

December 09, 2021 2:25 IST | India Infoline News Service
Dishman Pharmaceuticals
Dishman Carbogen Amcis has welcomed the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing blood lymphocyte percentages.

The research was supervised by Tehran University of Medical Sciences and Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly-owned subsidiary CARBOGEN AMCIS B.V.

“A person’s vitamin D status is defined as the person’s blood level of the vitamin’s 25-hydroxy metabolite (Calcifediol), i.e. the vitamin’s natural form in circulation which the body can quickly access and finally activate. Therefore, Dishman Carbogen Amcis Ltd has for years studied the effects of dosing either the vitamin and/or the metabolite. Said Dr Scott Miller, Sr. Scientific Advisor at DCAL, “Our support of this study of Calcifediol in the context of COVID-19 was motivated by the fact that the blood level of the metabolite can be increased more rapidly and more distinctly if supplemented directly.”

The study showed that patients receiving the 25-hydroxy metabolite had, in comparison to those receiving a placebo, demonstrably more favourable development of their immunological defence against COVID-19. Thus, dosing the metabolite significantly increased the blood levels as well as the comparative percentage of lymphocytes in the blood, i.e. a reduced Blood Neutrophil-to-Lymphocyte Ratio.

To support the Clinical Research Study CARBOGEN AMCIS B.V. (Netherlands) provided the Active Pharmaceutical Ingredient (Calcifediol) and the capsules and placebo were made at Dishman Carbogen Amcis Ltd’s plant in Bavla, India, specifically for this study.

“There are several studies that have reported that a good vitamin D status i.e. a healthy blood level of 25-hydroxyvitamin D, can not only dramatically reduce the risk of being infected by this deadly virus but also a higher vitamin D status reduced risk for serious symptoms and death caused by the virus.” Commented Dr Michael Holick. “This controlled study similar to the one conducted in Spain recently [1] demonstrate that the rapid improvement in vitamin D status can improve positive outcomes for patients infected with COVID 19.”

At around 2.22 pm, Dishman was trading at Rs244.30  per piece flat compared to the previous closing on Sensex. The stock has touched an intraday high of Rs247.30 per piece. 

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity